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1. INTRODUCTION 
 
1.1 Basics  
  
1.1.1 Adenosine1, 2, 3 
 
 
 
Fig.1 Adenosine 
 
Adenosine is an endogenous key molecule, consisting of the purine base adenine, 
linked to the monosaccharide -D-ribose. Adenosine is omnipresent in all species 
and plays a pivotal role in numerous biochemical processes such as signal 
transduction pathways as cyclic adenosine monophosphate (cAMP), as inhibitory 
neurotransmitter in the central nervous system and as energy carrier necessary to 
sustain living systems.  
Adenosine inhibits the release of excitatory and activating neurotransmitters like 
dopamine, acetylcholine, or noradrenaline, causing vasodilatation, thus reducing 
blood pressure. Furthermore, adenosine decreases heart frequency and prolongs 
conduction time (PQ) in the sinoatrial node, making it a diagnostic drug for 
testing and/or treating different types of supraventricular tachycardia.  
Adenosine has also sleep inducing properties by activating the ventrolateral 
preoptic nucleus (VLPO), a group of neurons in the hypothalamus releasing the 
inhibitory neurotransmitters galanin and GABA as well as inhibiting other 
neurons involved in wakefulness.      
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Adenosine can be attached to one, two or three phosphate groups building 
adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine 
triphosphate (ATP). ATP is an energy rich molecule due to its two reactive 
phosphoanhydride bonds of the triphosphate unit. When hydrolyzed, large 
amounts of free energy are liberated, used for almost all energy-consuming 
processes like motion, active transport, or biosynthesis.  
  
  
1.1.2 Adenosine receptor types1, 2, 4, 5, 16 
 
To date, four different adenosine receptor subtypes have been identified in several 
mammal species, including man. All of them are G-protein-coupled receptors, 
consisting of seven transmembrane domains. They are called P1-purino receptor 
and are distinguished from the P2-purino receptors that bind the nucleotides ADP 
and ATP.                                                                                                                                     
 
The A1 receptor subtype is expressed in the entire central nervous system and 
shows highest levels in the cerebral cortex, hippocampus, cerebellum, thalamus, 
and brain stem activating K+ channels and inhibiting Ca2+ channels - both of 
which reduce neuronal activity.25, 26 
 
The A2A receptor subtype is expressed only in few regions of the brain at high 
levels, namely the dorsal and ventral parts of the striatum17, 18 (Nucleus caudatus, 
Putamen and Nucleus accumbens) activating adenylyl cyclase. 
 
The A2B receptor is ubiquitous in the brain27, which makes it difficult to connect it 
to specific physiological and behavioural properties, because there are only few 
known specific A2B agonists and antagonists. The A2B receptor activates adenylyl 
cyclase. 
 
The A3 receptor subtype is little investigated, however it is believed to uncouple A1 
and metabotrope glutamate receptors via protein kinase C, thus modulating 
activity of other receptors.  
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Recent studies showed that the adenosine A3 receptor is expressed in almost all 
kinds of tissue like brain, heart, liver, kidney, or intestines.  
Since most studies are based on mere mRNA quantification, only little 
information regarding absolute receptor distribution and density is available.14 In 
the attempt of developing new techniques of quantification of the adenosine A3 
receptor, positron emission tomography (PET) proved to be the most suitable 
method, although suitable radioligands were required to perform this task.                   
 
Fig.2 Possible drug targets for adenosine receptor subtypes5 
 
 
1.1.3 The adenosine A3 receptor and pathological conditions1, 2, 16  
 
The adenosine A3 receptor is present in almost all kinds of tissue associated with 
many diseases like heart7 and brain ischaemia8, glaucoma9, stroke10 and epilepsy11. 
It is also involved in chronic inflammatory processes, asthma, and cancer12. 
Recent studies showed the A3 receptor is expressed at high levels on the surface of 
4 
 
primary and metastatic tumour cells19, 20, 21, 22, 23, 24, making it a promising target 
for future anti tumour compounds as well as tumour imaging techniques.13 
 
 
Fig.3. Schematic of the adenosine receptor types A1, A2A, A2B, and A315  
 
1.2 Radioactive Decay28, 29 
 
Radioactivity is the ability of an unstable atomic nucleus to lose energy by 
emitting ionizing particles or gamma radiation. This results in the transmutation 
of the so-called parent nuclide into another chemical element, called the daughter 
nuclide. The process of radioactive decay is spontaneous and random, which 
means predicting the decay of a certain atom is not possible, but in a large number 
of given atoms it is possible to predict the rate of decay in average over all atoms. 
The probability of radioactive decay is expressed by the half-life, defined as the 
time in which 50 percent of a given number of unstable nuclides have undergone 
radioactive decay. Half-life is constant and characteristic for each unstable 
element. Half-lives vary widely, from 10-23 seconds for highly unstable nuclides to 
1019 years for 209Bi.   
The SI unit is Becquerel (Bq), which is defined as one decay per second, but 
usually Gigabecquerel (GBq) is used as to the large number of atoms in regular 
samples of radioactive material.  
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The cause for the instability of some elements lies in the composition of the 
nucleus. A nucleus is composed of neutrons and protons that are controlled by the 
strong nuclear force, the electrostatic force and, in case of beta decay, by the weak 
force. If the balance between them is disturbed, the nucleus releases its energy 
either as gamma radiation photon or as particle like an alpha particle or a 
positron. This transformation alters the structure of the nucleus, yielding an 
element of higher stability.  
 
 
1.2.1 Modes of decay28,29,30, 32, 33, 34, 35 
 
Dependent of the composition of the radionuclide, different modes of decay are 
possible. We distinguish between decay emitting nucleons, like alpha decay,  the 
emission of an electron or positron called beta decay and the emission of high 
energy photon emission with no matter emitted at all, called gamma decay.    
 
 
1.2.1.1 Alpha decay32 
 
Alpha decay is the type of decay in which an atomic nucleus ejects an alpha 
particle, which is a helium nucleus. In this process, an atom with a mass number 
(A) minus 4 and atomic number (Z) minus 2 is formed as shown below. 
 
𝑋𝑍
𝐴  →  𝑌𝑍−2
𝐴−4 +  𝛼2
4   
 
The helium nucleus is a doubly charged helium atom; therefore, alpha radiation is 
a form of ionizing particle radiation. The alpha particle has a typical kinetic energy 
of 5 MeV and leaves the nucleus at a speed of approximately 15, 000 - 20, 000 
kph. The remaining nucleus sometimes remains in an excited state emitting 
gamma photons in order to remove the excess energy.  
Alpha decay usually occurs in heavy elements like uranium, thorium, radium, and 
the transuranium elements and must have a minimum-size atomic nucleus. The 
lightest elements ever observed to emit alpha radiation are the nuclides of 
tellurium with mass numbers of 106 to 100. 
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As for their large mass and low velocity alpha particles interact with other atoms, 
eventually losing their energy – which is the reason why they can be easily 
shielded by a sheet of paper or a few centimetres of air. Although alpha radiation 
is unable to penetrate skin and therefore is relatively harmless when exposed from 
outside, inhaling or by food intake can cause severe damage to living cells. Due to 
its strong ionizing properties and long half-life, this type of radiation is unsuitable 
for diagnostic purposes.  
 
 
1.2.1.2 Beta decay33, 35 
 
Beta radiation is, similar to alpha decay a type of high-energy ionizing radiation, 
caused by electrons or positrons emitted by radioactive nuclei with an excess of 
neutrons or protons. If an electron is emitted it is referred to as beta minus (), 
while in case of a positron emission as beta plus (). Unlike in alpha decay, beta 
decay is neither governed by nuclear nor electromagnetic force, but by weak 
interaction.  
 
In beta minus () decay, a neutron is converted into a proton, while emitting an 
electron (e-) and an electron antineutrino (𝑣 e). An atom with the same mass 
number (A) and atomic number (Z) plus 1 is formed as shown below.                          
 
𝑋 →𝑍
𝐴  𝑌𝑍+1
𝐴 +  𝑒− +  𝑣 𝑒   
  
In beta plus () decay, a proton is converted into a neutron, a positron (e+) and a 
neutrino (ve). An atom with the same mass number (A) and atomic number (Z) 
minus 1 is formed: 
  
𝑋 →𝑍
𝐴  𝑌𝑍−1
𝐴 +  𝑒+ +  𝑣𝑒   
 
The emitted positron is not very stable when in contact with matter, leading to an 
annihilation event once the positron collides with an electron. In this process, two 
gamma ray photons of 511 keV are being produced and emitted in opposite 
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direction. These two gamma photons are used for positron emission tomography 
(PET). 
 
 
Fig.4 Annihilation (modified)36 
 
A related mode of decay is the electron capture which, like beta plus decay, occurs 
in a nucleus containing too many protons, but unlike in beta plus decay, the 
energy necessary to emit a positron is insufficient - that is an energy difference of 
parent and daughter nuclide less than 1.022 MeV.                                                             
Instead, an orbital electron is captured by a proton and converted to a neutron 
and a neutrino (ve). Since the proton is changed to a neutron, the mass number 
(A) remains unchanged and the atomic number (Z) is decreased by 1, 
transforming the nuclide into a new element: 
 
𝑋𝑋 +  𝑒𝑒−  →𝑍𝑍𝐴𝐴  𝑌𝑌𝑍𝑍−1𝐴𝐴  +  𝑣𝑣𝑒𝑒  
 
If the resulting kinetic energy is not transferred entirely to the neutrino, the newly 
created nuclide remains in an excited state. When transiting to the ground state, a 
gamma photon, and/or Auger electron is emitted.   
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Beta radiation has more penetrating powers than alpha radiation, but is far less 
penetrating than gamma radiation, although its ionising powers are stronger due 
to its composition of charged particles. The energy released by beta particles 
varies, but the typical maximum energy is approximately 1 MeV. Nevertheless, 
they can be stopped by a few millimetres of aluminium. Passing through matter 
decelerates beta particles by electromagnetic interactions, which may cause 
bremsstrahlung gamma radiation. 
  
Beta particles penetrate the skin and can severely damage the skin layers, causing 
burn and long-term effects such as cancer. If beta particles are taken up internally, 
high radiation contamination in the surrounding tissue can occur, which has been 
proven for thyroid cancer as long time effect from 131I exposure. Exposing of the 
eyes to beta radiation can cause cataract. The accumulation of radioactive 90Sr in 
the skeleton is believed to cause bone cancer and leukaemia.  
Ironically, beta particles are used in radiation therapy to treat several kinds of 
cancer as to their ability to kill cancer cells as well. 
Another field of application is medical imaging, in which certain tracer molecules 
are used as source for positrons yielding from beta plus () decay.  
  
 
1.2.1.3 Gamma radiation34 
 
Gamma radiation is electromagnetic radiation of high frequency and short 
wavelength. It is caused by subatomic particle interactions such as electron-
positron annihilation, neutral pion decay, radioactive decay, fission, fusion, or 
inverse Compton scattering. Typical gamma ray frequency is above 1019 Hz; 
therefore, the wavelengths are less than 10 picometres and energies above 100 
keV. Gamma rays caused by radioactive decay usually have energies between a few 
100 keV and less than 10 MeV. Gamma radiation is ionizing radiation, such as 
alpha or beta radiation, but of more penetrating powers.  
In the past, gamma rays were distinguished from X-rays based on energy 
amounts, considering gamma rays as more powerful than X-rays. Nevertheless, as 
energy ranges overlap widely, this distinction became obsolete. The two are the 
same in essence, the only difference between them being their creation process. 
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Gamma rays are caused by nuclear decay, whereas X-rays are emitted by electrons 
in orbitals outside the nucleus or when accelerated to produce bremsstrahlung 
radiation.   
Gamma radiation is the most penetration radiation, requiring heavy shielding31 to 
be protected against it. Large amounts of mass are necessary. Elements with high 
density and high atomic number are ideal. The probability for absorption is 
proportional to the thickness of the shielding, leading to an exponential decrease 
of radiation intensity with thickness. Lead is a very dense metal, yet cheap and 
compact, making it adequate for that purpose. Concrete is more suitable for large 
radiation sources and depleted uranium is applied in portable gamma ray sources 
in order to reduce bulkiness.  
Gamma radiation, like any ionizing radiation, is harmful for organic life, causing 
damage at a cellular level. Alpha and beta radiation, however, are less dangerous, 
because they cannot penetrate the body easily and mostly cause localized damage 
like radiation burn to the skin. Gamma radiation penetrates the body easily, 
therefore causes damage to the DNA. Subsequently, this leads to interference with 
the cell’s ability to divide and duplicate, rather than instantaneous cellular 
breakdown. This effect can be observed in fast proliferating cells such as 
enterocytes, hair follicles, or skin cells within a short period. Cellular necrosis 
occurs, ranging from minutes to days, depending on the level of exposure, whereas 
in slowly proliferating cells this effect might be observed years later. The reason 
for this is the inability of the remaining stem cells to duplicate; therefore, this 
effect is immediate in cells with fast division cycle and late in slowly duplicating 
cells. These symptoms are called radiation sickness or radiation poisoning. 
Despite its devastating effect on living tissue, gamma radiation of all types of 
radiation has the widest field of application. It is used for sterilizing single-use 
medical equipment such as syringes or needles or sterilizing food cans, chemical 
sciences make use of gamma radiation in x-ray-crystallography for structural 
determination of many inorganic and organic molecules including biopolymers 
such as proteins. It is also used in industrial radiography as material testing 
method for structural damage, debris, or corrosion. Gamma ray detectors are used 
at airports to screen people and luggage and at harbours to screen ship containers.  
Its medical application includes many imaging diagnostic techniques like x-ray 
radiography, computed tomography (CT), single photon emission computed 
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tomography (SPECT), as well as means of treatment for cancer including gamma-
knife surgery and brachytherapy. 
 
 
1.2.2 Natural radiation37 
 
Background radiation is omnipresent in our environment, emitted from natural 
sources and artificially created ones. Natural sources mainly have two origins, 
cosmic radiation, and terrestrial sources. 
Radiation from outer space is generated, when positively charged ions from 
outside the solar system hit the atmosphere. Secondary radiation, including 
gamma radiation, protons, alpha particles, electrons and neutrons, is created. The 
dose varies in different parts of the planet, depending on the altitude and the 
geomagnetic field. In the upper troposphere at around 10 kilometres, the altitude 
where passenger aircrafts travel, the radiation is more intense, posing a certain 
danger for long-distance flight crews and frequent passengers.     
Cosmic radiation also causes elemental transmutation by interaction with atomic 
nuclei in the atmosphere. The most relevant are the 14C isotopes, which are 
produced by interaction with nitrogen atoms. Eventually, they reach the earth 
surface and become incorporated to living organisms. This is the foundation of 
radiocarbon dating.  
On earth, radioactive isotopes are present in soil, rocks, water, air, and vegetation 
and were formed billion years ago by stellar nucleosynthesis. These radioactive 
isotopes can be from common elements like potassium (40K) or carbon (14C) or the 
long-lived elements such as uranium (238U) or thorium (232Th) and their decay 
products like radium or radon. The level of radiation varies depending on the area. 
Some locations have significantly higher background radiation like Kerala in 
India, Yangjiang in China or Ramsar in Iran. The latter has up to 200 times 
greater background radiation than in average, due to hot springs in the 
surrounding area that are used as spas. Nevertheless, there seem to be no ill 
effects on the residents associated with the excessive radiation; on the contrary, 
the locals seem to be slightly more radio resistant. Based on this „radiation 
paradox“, some scientist suggest that the „linear no-threshold model“, on which 
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all radiation regulations are based, is not valid and that a certain amount of 
radiation might be beneficial for health.51, 52  
 
 
1.2.3 Artificial radiation37, 38 
 
All kinds of artificial radiation are man-made radiation and identical in their 
nature and their implications and add to the natural occurring radiation. Sources 
are nuclear facilities like nuclear power plants (especially the Chernobyl incident), 
medical imaging, and radiotherapy, fallout from nuclear weaponry testing and 
research facilities. The creation of radioactive isotopes is accomplished by 
bombardment of a nucleus with alpha particles, protons, neutrons, or gamma 
radiation photons, leading to the artificial transmutation. The created 
radionuclides do not exist on earth naturally and, as result of their short half-lives, 
have to be created in-situ for each application purpose. E. Rutherford created the 
first artificial nuclei in 1919. Only long-lived radionuclides or stabile nuclides are 
suitable as parent nuclides. To assure appropriate purity of the relevant 
radionuclides for medical purpose, it is necessary to establish a suitable 
irradiation technique as well as a proper radiochemical work-up process to assure 
high yield and adequate purity. This is even more important if the desired product 
is accessible only over more steps.                                                                                         
Several ways of producing the desired radionuclides have been developed. 
Neutron-rich nuclides either yield from nuclear fission as decay product or are 
created by neutron irradiation of the parent nuclides. Neutron-poor nuclides are 
generated using either a cyclotron or a generator.  
  
 12 
 
1.2.4 Production of radioactive nuclides 
 
 
1.2.4.1 Radionuclides produced by nuclear reactor29, 38 
 
Nuclear fission is a process of splitting unstable and highly excited nuclides of 
high atomic masses in two or more fragments of medium atomic masses and the 
release of energy as electromagnetic radiation and kinetic energy of the fragments. 
Free neutrons and protons evolve as by-product. This process of transmutation 
takes place in a nuclear reactor. Fission occurs spontaneously (as radioactive 
decay) or can be induced by a neutron flux that hits a placed element inside the 
reactor. The neutrons are absorbed by the element that is gaining nuclear binding 
energy, thus promoting to an excited state and eventually splitting into fragments. 
The emerging nuclides are neutron-rich and undergo beta minus decay. The most 
important nuclides are 3H (t1/2 = 12,3 y), 14C (t1/2 = 5730 y), 33P (t1/2 = 25,3 d), 35S 
(t1/2 = 87,5 d) and 125I (t1/2 = 59,4 d), all of which are used for scientific and 
medical purposes; 3H and 14C are used in liquid scintillation counting and 
frequently used for biochemical tasks; 125I is often applied in radio immuno assays 
(RIA), whereas 33P and 35S are used in metabolic assays.    
 
 
1.2.4.2 Radionuclides produced by radionuclide generator38, 42 
 
Radionuclide generators provide an economic and space-saving method of 
obtaining short-lived radionuclides, while solving the problem of not being able to 
transport short-lived radionuclides from a distant nuclear reactor to the PET 
facility. A parent nuclide with long half-life is used as source to obtain the 
daughter nuclide that can be eluted.  
The generator system consists of a small glass tube filled with ion exchanger 
matrix retaining the parent nuclide. Both ends of the tube contain a membrane 
disk filtering particles. The nuclide can be eluted by attaching an evacuated 
injection vial.  
After the daughter nuclide has been eluted, the parent begins to regenerate, so 
that the daughter nuclide can be obtained repeatedly.  
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The following prerequisites must be fulfilled to build a viable generator system:  
 
• Half-life of the parent nuclide should be much longer than half-life of the 
daughter nuclide, as the lifetime of the generator is determined by the half-
life of the parent nuclide  
• The chemical properties of the parent nuclide must not change after 
repeated elution of the daughter nuclide 
• The obtained daughter nuclide must provide high radiochemical purity 
during the lifetime of the generator system.  
 
Popular generator systems are 99Mo/99mTc generator, 81Rb/81mKr generator and 
68Ge/68Ga generator. 99mTc is widely used in single photon emission computed 
tomography (SPECT) due to its short half time.  
 
 
Fig.5 Generator, schematic modified42 
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1.2.4.3 Radionuclides produced by particle accelerator 
(cyclotron)39, 42  
 
A cyclotron is a particle accelerator used to obtain neutron-poor radionuclides for 
PET imaging. In a vacuum chamber, 1H- or 2H- ions are accelerated using a high 
frequent alternating voltage applied. A perpendicular magnetic field forces the 
particles in a spiral motion. At the perimeter of the vacuum chamber, the 
electrons are stripped off by a stripper foil to hit the target material, which can be 
liquid, gaseous, or solid, causing the transmutation into the desired radionuclide. 
Commonly used PET nuclides are 18F, 11C, 13N, and 15O.  
 
 
Fig.6/7 Cyclotron, schematic40, 41 
 
A cyclotron consists of a large electromagnet around a flat vacuum chamber 
between the two poles. Inside the chamber, a high frequency alternating voltage is 
applied across the „D“ electrodes (also called dees). The alternating voltage 
present in the gap accelerates the particles, which are injected from an ion source 
at the centre of the dees. The metal of the „D“ electrodes acts as Faraday shield, 
hence there is no electric field present inside the dees. The magnetic field runs 
perpendicularly to the D electrode and forces the accelerated particles to move in a 
spiral path. The particle beam leaves the spiral at the perimeter of the electrodes 
and hits the target.  
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1.3 Radiopharmaceuticals in functional diagnostic43 
 
Nuclear medicine exists for over 50 years and involves both therapy and 
diagnostics using open radionuclides. Two assumptions must be made in order to 
successfully employ radionuclides. First, the organism would not distinguish 
between the radioactive isotope from the natural occurring element; therefore it 
would metabolize them equally; second, the amounts of radionuclides used would 
be small enough that no interference with the metabolism would be observed.  
Thus, functional diagnostic employing radionuclides is based on a different 
principle than conventional medical imaging. The latter only captures static 
images of an organ like bones or pathological tissue, whereas functional diagnostic 
is able to trace a radiolabelled compound in the body over time, making its 
metabolism and distribution visible. Conventional nuclear imaging techniques use 
isotopes with short half time such as 123I, 111In or 99mTc, detected by gamma camera 
(also called scintillation camera or Anger camera).  
Recently, PET is gaining more relevance because of its superior spatial resolution. 
The most commonly used radio isotopes in PET are 18F, 11C, 13N, and 15O. 
 
 
1.4 Positron emission tomography (PET)38, 44, 45, 46, 47 
 
Positron emission tomography (PET) is a non-invasive imaging technique, used 
for quantitative measurement of biological processes such as enzyme activity, 
receptor density, and occupancy or rate of biosynthesis in vivo. PET can be a 
valuable instrument in drug development and evaluation of drug efficacy. PET 
supported study of the adenosine receptor system is an important technique to 
track down neurological and behavioural diseases in the future and lead to a 
deeper understanding of pathways of neurotransmission. This is achieved by 
administration of positron emitting tracers. These are biological molecules tagged 
with radionuclides, favourably with no structural change of the molecules 
themselves. The most commonly used radio isotopes are 18F (t1/2 = 110 min.), 11C 
(t1/2 = 20 min.), 13N (t1/2 = 10 min.) and 15O (t1/2 = 2 min.). Due to the short half-
life, it is imperative to have access to a nearby radiochemical laboratory and a 
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cyclotron for production purposes. The amounts of injected PET tracers are small 
enough (nanomolar concentration) to use highly active compounds without the 
risk of triggering any pharmacological effect.    
 
 
1.4.1 Development of PET38, 47 
 
In 1963, approximately 10 years prior to the first use of the x-ray computed 
tomography (CT), Kuhl and Edwards described the Single-Photon-Emission-
Computed-Tomography (SPECT). Due to limited spatial resolution of the first 
SPECT images, this technique was inferior to CT. At the early stages of SPECT 
imaging, the patient had to turn around in front of the camera, deteriorating the 
early images. Eventually, SPECT scanners with rotating heads have been 
developed, moving the camera around the patient. Today, using dual or triple 
headed SPECT systems is standard, mounted on a circular arc. This results in 
greater sensitivity and reduced scanning time as well as decreased amounts of 
tracer needed. These improvements combined with greater mechanical stability of 
modern systems decreased routine scan time from 40 to 10 minutes, making them 
more cost effective.                                                                                                                     
For cardiac purpose, the detectors are mounted right-angled. Moving examination 
beds and mobile camera tripods make dual and triple headed SPECT machines 
suitable for whole-body scintillation imaging.                                                                    
 
In 1962, Rankovitz and Robertson did the first PET brain scan using a device 
composed of 32 NaI detectors arranged in a ring.48  
In the 1970s, the world’s first commercial PET scanner was developed by Ter-
Pogossian, Phelps and Hoffman49 while Ido, Reivich and Phelps established the 
preparation and application of 2-deoxy-2-(18F)fluoro-D-glucose, the most widely 
used and versatile PET tracer.50  
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1.4.2 Advantages and disadvantages of PET vs. SPECT47, 53, 54, 55 
 
PET is similar to SPECT in its use of radioactive tracers, but unlike in SPECT, 
gamma rays are not emitted directly by the tracer and measured by a gamma 
camera, but indirectly as secondary event in the annihilation process. An emitted 
positron travels a few millimetres before it collides with an electron, causing two 
gamma photons to be emitted at almost 180 degrees to each other. A PET scanner 
detects these photons simultaneously („in coincidence“), allowing to localize their 
origin along a straight line, called line of response (LOR).  
 
In SPECT technology, the image is generated using projections from many 
directions, usually every 3-6 degrees recorded by a rotating camera. Acquiring 
sharp images requires the use of collimators, components capable of filtering a 
gamma ray stream, allowing only the gamma photons parallel to a certain 
direction to pass and hit the detector. Nevertheless, filtering over 99 % of the 
emitted rays has a highly negative impact on the signal-to-noise ratio leading to 
strong degradation of image quality. 
PET, in contrary, does not use collimators, giving a better gamma photon yield, 
faster detection rate, better image quality, and improved spatial resolution 
compared to SPECT.  
Furthermore, PET allows to quantifying tracer distribution patterns, which is not 
possible in SPECT, enabling the absolute quantification of myocardial blood flow 
measurement or coronary flow reserve measurement.  
SPECT, however is a less pricey technology, the costs are around one third of PET 
machines, mainly because of two reasons. First, the scanner contains less 
sophisticated electronic components and second, the usage of easily obtained 
gamma-emitting radioisotopes with longer half-lives saves the trouble of 
maintaining a highly expensive cyclotron and specially adapted on-site chemical 
synthesis apparatus to produce the required radionuclides.  
Recently, SPECT is experiencing a renaissance, having overcome some of its 
inherent flaws by newly developed SPECT/CT hybrid machines, while preserving 
its cost advantage. 
Today, both SPECT and PET are used in clinical examinations, both for similar 
indications.  
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1.4.3 Application of PET54 
 
PET is a powerful instrument in both medicine and research. As medical 
instrument, it is widely used in neurology, cardiology, and oncology. Neurological 
diseases like Alzheimer’s disease, Parkinson‘s disease, Chorea Huntington and 
epilepsy can be diagnosed in early stages and progression of these diseases can be 
made visible. Brain damage after a stroke can be evaluated by measuring the 
blood flow to different parts of the brain using 15O as tracer. In the future, when 
more suitable radioligands for different neuroreceptor subtypes have become 
available (e.g. the dopamine or adenosine receptor), it is conceivable to map the 
brain more precisely, visualizing several kinds of brain damage arising from many 
neurological and psychiatric diseases, virtually undetectable by conventional 
SPECT/CT scans.    
In cardiology, PET is helpful in studying atherosclerosis and related vascular 
diseases. It is also used to visualize blood flow within the coronary arteries, 
displaying cardiac stenosis as well as metabolic activity of the myocardium.  
Most important, however, is the application of PET in clinical oncology, using 2-
deoxy-2-(18F)fluoro-D-glucose (commonly abbreviated 18F-FDG or FDG) as 
standard tracer. It is a glucose analogue taken up by glucose using cells. Tumour 
tissue has an elevated glucose uptake due to its rapid cell proliferation rate; this is 
the reason why it is accumulated in cancer cells as well as in organs of high 
glucose utilization, such as brain or liver. Yet, a PET scan is not the method of 
choice to search for cancer as a routine medical check-up. That is, aside from high 
costs involved, because of normal inflammatory processes that lead to accelerated 
glucose metabolism as well, hence cannot be distinguished from tumour tissue in 
a PET image. Nevertheless, metastasis can be made visible, making it an ideal 
instrument for staging and monitoring of cancer. It is also used to assess cancer 
treatment success, particularly of Hodgkin’s lymphoma, non-Hodgkin’s 
lymphoma, lung cancer and several other kinds of solid tumours.      
 
The role of PET in pharmacology includes biodistribution studies in pre-clinical 
trials, when radiolabelled new drugs are injected into small animals to trace a 
possible new drug inside the body. Distribution, tissue concentration, and 
elimination of the compound can be discovered very quickly and cost-effective. 
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Moreover, drug occupancy at a specified target can be inferred indirectly by 
competition studies between unlabelled drug and a radiolabelled compound 
known to bind.  
 
 
1.4.4 Hybrid Technology54 
 
Recently, large efforts were made to combine the best of both worlds, by coupling 
SPECT and/or PET with conventional CT. The latter is used to calculate the 
attenuation map, necessary to correct for the photons absorbed by overlying 
tissue. Additionally, the CT provides valuable anatomical information, while PET 
gives the physiological information. The result is a more detailed image by 
merging the two, enabling a more accurate diagnosis, as well as shortening scan 
time. The increased accuracy and image quality of PET/CT or SPECT/CT 
machines can also help avoiding unnecessary surgery; it allows better 
determination of patient’s response to therapy and more precise guiding of 
radiation therapy. Newly developed PET/CT hybrids are also capable of taking 4D 
images, which means taking images of moving anatomical structures, such as 
heart or lungs. 
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1.4.5 Production of [18F]-radiolabelled synthesis precursors for 
PET56, 57, 58 
 
The successful development of a novel PET tracer requires observing following 
aspects: 
 
 choice of labelling position in the tracer molecule 
 stereochemical properties 
 specific activity 
 choice of the cyclotron produced primary precursor and online production 
of the secondary precursor 
 chemical properties of the precursor, including the choice of the solvent 
 choice of solvent for the pharmaceutical formulation (pH adjustment to 
physiological state and osmolality) 
 expected clinical outcome of the nuclear medicinal question  
 
One important aspect of developing novel PET tracers is the specific activity of the 
radioligand. The specific activity is defined as ratio of the radiolabelled molecules 
to the total number of molecules. The higher the specific activity of a radioligand 
is, the fewer molecules need to be applied for the PET imaging process and the 
less interference with the observed biological process occurs. This is of great 
significance in measuring receptor density and distribution patterns as well as 
enzyme level tests.57        
 
Production of all PET radiotracers starts with small cyclotron obtained precursor 
molecules. Yet, the number of the resulting precursor molecules of the four 
commonly used radionuclides 11C, 18F, 13N, and 15O is limited due to extreme 
conditions in the cyclotron target. As the chemical form is determined by high 
energy, the irradiation leads to stable and rather unreactive molecules. There are 
many ways of producing the desired radionuclides, but usually only one or two 
different nuclear reactions are favoured. 
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The 18F nucleus is the most relevant in this thesis and usually produced in either of 
two ways.59 One is the 20Ne(d, )18F nuclear reaction on a target of pressurized 
neon gas using a nickel target body to obtain [18F]F2, the diatomic and highly 
reactive species of 18F.60  
The other, more widely used is the 18O(p, n)18F nuclear reaction on a H218O target 
using a target body of pure silver or titan. After irradiation, 18F is obtained as 
fluoride ion ([18F]F-) in aqueous solution and can be used for further reactions in 
aqueous solution or can be separated from H218O by distillation or using ion 
exchanger resin.61, 62, 63 
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1.5 18F radiolabelling techniques 
 
 
1.5.1 Nucleophilic fluorination64 
 
The [18F]F- ion derived from the aqueous solution is used for nucleophilic 
fluorination. Nevertheless, the fluoride ion is unreactive, because of its high 
charge density and the large surrounding hydration shell. In order to remove 
H218O and interfering metal ions from the target body, anionic exchanger resin is 
used.65, 66, 67 Then the [18F]F- is eluted by a solution of K2CO3 and the cryptand 
„Kryptofix 2.2.2™“ in an acetonitrile/water mixture (7+3). After the elution, 
additional acetonitrile is added to get an acetonitrile/water mixture (85+15), 
which can be removed easily by azeotropic distillation under an inert gas stream. 
The cryptand complexing the [18F]F- can then be transferred to a suitable organic 
solvent for further reaction.                                                                                                     
 
The displacement of different leaving groups by [18F]F- is an excellent choice of 
forming aliphatic Carbon-Fluor bonds.68 Selecting a suitable leaving group 
depends on accessibility of the molecule, stability of the precursor, the method of 
isolating the 18F labelled product, reagents, solvent, and formation of by-products. 
Especially trifluoromethanesulfonate esters are characterized by high reactivity 
and lead to high yields in nucleophilic fluorination as in the preparation of 2-
deoxy-2-(18F)fluoro-D-glucose. Halides such as  Cl-, Br-, I- are also good leaving 
groups and widely used, whereas tosylate and mesylate groups sometimes are a bit 
lower yielding.56 
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1.5.2 Electrophilic fluorination64 
 
The simplest way of fluorination via electrophilic attack by 18F is the preparation 
of [18F]F2 as described above. The most significant problem of using the diatomic 
species, however, is its extremely high reactivity, associated with low selectivity. 
The exothermic reactions need appropriate cooling or the use of highly diluted 18F 
solutions. A more feasible way is the conversion into less reactive functional 
groups such as in acetyl hypofluorite69 or xenon difluoride70. Despite its 
disadvantages, the electrophilic fluorination is well established in PET tracer 
development. 
 
 
1.5.3 Fluoroalkylations56, 71 
 
Many biologically active compounds contain alkyl side chains like methyl or ethyl 
groups suitable for radionuclide labelling. Since there are many [11C] methyl 
tracers available, development of [18F]alkylated analogues was the next logical 
step. To do so, a number of [18F] alkylating agents were developed. [18F]bromo 
fluoromethane, [18F]fluoro iodomethane, 2-[18F]bromo fluoroethane, 2-
[18F]tosyloxy fluoroethane are a few to mention. The radioligands [18F]FET (O-(2-
[18F]fluoroethyl)L-tyrosine) and [18F]FP-CIT (N-(3-[18F]fluoropropyl)-2β-
carbomethoxy-3β-(4-iodophenyl)nortropane) are already in clinical use. 
 
 
1.5.3.1 Fluoroethylations 
 
Fluoroethylations are the most relevant among the fluoroalkylations, because 
fluoroalkylation reagents can be produced easily by low priced and widely 
available precursors. Additionally, the fluoroethyl group strongly resembles both 
the methyl and ethyl group. Popular targets for fluoroethylations are amine-, 
hydroxyl-, mercapto- and carboxyl groups, using reagents such as [18F]tosyloxy 
fluoroethane, [18F]fluoro ethyl  trifluoromethanesulfonate or [18F]tosyloxy 
fluoroethane.  
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2. MY OWN RESEARCH 
 
2.1  Aim of my research 
 
Based on the results of Li et al74, who investigated the selective binding of pyridine 
derivatives as antagonists to the adenosine A3 receptors, [18F]FE@SUPPY seems 
to be an appropriate candidate to act as selective radiotracer of high affinity.74 
This compound has a sulfanyl-phenyl-pyridine structure of which derives the 
abbreviation SUPPY and is radiolabelled using 18F on the carboxyl group. A 
structural related compound is [18F]FE@SUPPY:2, which is radiolabelled on the 
thiocarboxylic side, expected to yield an even better receptor affinity. Many 
related compound have been synthesized to date, trying to modify the lipophilicity 
of the SUPPY molecule in order to achieve better receptor binding quality.  
The aim of my research was the preparation of two novel SUPPY derivatives.  
They are 2-fluoroethyl 4,6-diethyl-5-{[(2-fluoroethyl)thio]carbonyl}-2-
phenylnicotinate (10) and methyl 4,6-diethyl-5-{[(2-fluoroethyl)thio]carbonyl}-
2-phenylnicotinate (11).                                                                                                           
Both compounds should serve as HPLC reference compounds and are candidates 
to be tested as novel PET tracers for the adenosine-A3-receptor.  
Furthermore, a new synthesis pathway to obtain to 4,6-diethyl-5-{[(2-
fluoroethyl)thio]carbonyl}-2-phenylnicotinic acid (8) was established. 
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2.2 Reaction scheme 
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2.3 Preparation of 4,6-diethyl-2-phenyl-5-
thiocarboxynicotinic  acid71 (7) 
 
The first desired compound was 4,6-diethyl-2-phenyl-5-thiocarboxynicotinic acid 
(also called SUPPY:0) (7), which can be considered the parent compound, 
allowing quick and easily performed modification with different side chains. 
SUPPY:0 alterations of the basic structure led to several PET precursors, of which 
some are already in use. The first six steps were carried out according to the 
dissertation of Shanab K., 2007, with some procedure modifications in order to 
increase the yield of SUPPY:0. 
 
 
2.3.1 Preparation of 3-allyl 5-(4-methoxybenzyl) 2,4-diethyl-6-
phenyl-1,4-dihydropyridine-3,5-dicarboxylate71 (2) 
 
 
 
In the first step, p-methoxybenzyl-protected and allyl-protected precursors were 
subjected to a Hantzsch pyridine synthesis. 4-Methoxybenzyl-3-amino-3-
phenylprop-2-enoate (1a), allyl-3-oxo-pentanoate (1c), and propionaldehyde 
(1b) were dissolved in absolute ethanol and stirred in the autoclave at 80°C for 24 
hours. The solvent was removed after cooling to room temperature and the crude 
product purified by liquid column chromatography eluting with ligroine/ethyl 
acetate 8+2.  
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2.3.2 Preparation of 3-allyl 5-(4-methoxybenzyl) 2,4-diethyl-6-
phenylpyridine-3,5-dicarboxylate71 (3) 
 
The second step employs the oxidization of (2) to the desired pyridine derivative 
(3), according to following scheme. 
   
 
3-Allyl 5-(4-methoxybenzyl) 2,4-diethyl-6-phenyl-1,4-dihydropyridine-3,5-
dicarboxylate (2) and 2,3,5,6-tetrachloro-1,4-benzoquinone were dissolved in 
THF and heated under reflux overnight. The reaction mixture was cooled down 
and the solvent removed under reduced pressure to give the desired pyridine 
derivative (3). The product was purified by using column chromatography eluting 
with ligroine/ethyl acetate 9+1.                                                                                               
 
2.3.3 Preparation of 2,4-diethyl-5-{[(4-methoxybenzyl)oxy] 
carbonyl}-6-phenylnicotinic acid71 (4)         
 
 
In the following step, the allyl protecting group was removed. The allyl ester 
function could be split off selectively by the use of transition metal 
tetrakis(triphenylphosphine)palladium and morpholine.  
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3-Allyl 5-(4-methoxybenzyl 2,4-diethyl-6-phenylpyridine-3,5-dicarboxylate (3), 
obtained from the previous step was dissolved in THF and 
then tetrakis(triphenylphosphine)palladium and morpholine were added under 
argon atmosphere. The mixture was stirred for 30 minutes at room temperature. 
Afterwards, the solvent was removed under reduced pressure. The obtained 
product required extensive purification operations. It was purified by liquid 
chromatography (silica gel 60) several times. First, an eluent mixture of 
dichloromethane/methanol 95+5 was used for separating the dark brown 
contamination from the product. Afterwards, an ethyl acetate/methanol 8+2 
mixture was used to elute the product faster. Several repetitions were necessary to 
achieve a satisfactory result. 
 
 
2.3.4 Preparation of 4-methoxybenzyl 5-(chlorocarbonyl)-4,6-
diethyl-2-phenylnicotinate71 (5)      
 
The product from the previous step (4) was used for converting the carboxylic 
acid group into the corresponding acid chloride (5). 
  
 
 
To   perform   this,   2,4-diethyl-5-{[(4-methoxybenzyl)oxy]carbonyl}-6-
phenylnicotinic acid (4) was dissolved in absolute toluene and injected via syringe 
to a three-necked-flask equipped with reflux condenser and thermometer under 
inert gas. The apparatus was then immersed in a Dewar vessel filled with a 
ethanol/dry ice mixture and cooled down to -20°C instead of -10°C of the original 
working instructions, hoping of an yield increase of the desired thiocarboxylate. 
Another modification was the usage of toluene instead of benzene as solvent 
mainly for two reasons. First, toluene is less toxic and second, toluene‟s freezing 
temperature is below that of benzene, assuming the reaction mixture would stay 
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liquid during the whole reaction. The more difficult removal of toluene at room 
temperature proved to be the only disadvantage over benzene.                                      
Then a few drops of DMF were added as catalyst and the oxalyl chloride injected 
drop wise via syringe. After removing the Dewar and reaching room temperature, 
the mixture was stirred for additional 30 minutes, eventually becoming a 
brownish liquid and stirred until the reaction was finished after approximately 
one hour. Afterwards, the solvent was removed under reduced pressure at room 
temperature. 
 
 
2.3.5 Preparation of 2,4-diethyl-5-{[(4-methoxybenzyl)oxy] 
carbonyl}-6-phenylpyridine-3-carbothioic S-acid71 (6)                 
 
 
The product obtained from the previous step (5) was subjected to the following 
reaction to give the desired thiocarboxylic acid. 
  
 
 
In a dry three-necked flask equipped with reflux condenser under inert gas 
atmosphere, comminuted NaHS.hydrate platelets were dissolved in absolute 
ethanol under moderate heating. After having become completely dissolved, the 
solution was immersed in a Dewar vessel filled with a ethanol/dry ice mixture and 
cooled down to -20°C, hoping the additional cooling, as in the step before, would 
help to increase the SUPPY:0 yield. Unfortunately, the attempt proved to be 
unsuccessful in both cases.  
The 4-methoxybenzyl 5-(chlorocarbonyl)-4,6-diethyl-2-phenylnicotinate (5) 
residue yielding from the previous reaction was dissolved in absolute THF and 
then added slowly via syringe under stirring. After the addition of the acid 
chloride had finished, the Dewar vessel was removed, allowing the reaction 
mixture to reach room temperature. The stirring was continued for a further hour, 
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during which the progress of the reaction was monitored by TLC. Afterwards, the 
orange solution was acidified by 6N hydrochloric acid. The aqueous layer was 
extracted thoroughly with ethyl acetate, washed twice with a saturated solution of 
sodium chloride, and dried over sodium sulphate. The solvent was removed under 
reduced pressure and the crude product purified by column chromatography 
several times eluting with a ligroine/ethyl acetate mixture 7+3. Almost colourless 
crystals were obtained.                                                                                                             
 
 
2.3.6 Preparation of 4,6-diethyl-2-phenyl-5-thiocarboxynicotinic 
acid71(7)                                                                                                            
   
 
The final step in the preparation of SUPPY:0 (7), the parent compound for novel 
PET tracer preparation, comprises of cleaving the p-methoxybenzyl protection 
group.  
 
 
 
 
For the desired deprotection, 2,4-diethyl-5-{[(4-methoxybenzyl)oxy]carbonyl}-6-
phenylpyridine-3-carbothioic S-acid (6) from the previous step was stirred in the 
presence of formic acid at room temperature for several hours. Then the formic 
acid was removed under reduced pressure. The crude product was purified by 
reversed-phase column chromatography several times, eluting with an 
acetonitrile/water mixture 95+5. Compound (7) was obtained as colourless 
crystals. 
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Unfortunately, this purification was hampered by a considerable reduction of yield 
(41%). Two alternate ways of cleaving the protection group were investigated in 
order to prevent this substantial loss of product.  
 
 
2.3.6.1 Deprotection with triethyl silane / trifluoroacetic acid73 
 
In order to prevent the substantial loss of SUPPY:0 during the deprotecting step, a 
different approach was tried using triethyl silane serving as carbocation scavenger.   
 
 
2,4-Diethyl-5-{[(4-methoxybenzyl)oxy]carbonyl}-6-phenylpyridine-3-carbothioic 
S-acid (6) was dissolved in dry dichloromethane in a three-necked-flask equipped 
with reflux condenser and thermometer under argon atmosphere and cooled 
down to 0°C in an ice bath. Then triethyl silane and trifluoroacetic acid were 
added via syringe. A considerable rise in temperature was not noticed. The ice 
bath was removed and the solution stirred for further two hours. The colour of the 
solution turned dark reddish-brown. The solvent was evaporated under reduced 
pressure and the crude product was purified by reversed-phase column 
chromatography several times, eluting with an acetonitrile/water mixture 95+5. 
Only about 41% of highly purified SUPPY:0 (7) resulted from this attempt. 
Considering the effort necessary to perform this preparation, this method is not 
preferable over the originally published method.  
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2.3.6.2 Deprotection with triethyl silane / formic acid73 
 
Based on the observation that in the previous attempt the reaction mixture turned 
darker during the reaction, it was suspected that TFA was a too strong 
deprotecting agent and would possibly lead to decomposition of the product. In 
consequence of this, TFA was replaced by formic acid, expecting an increase of 
yields of SUPPY:0 (7).                                                                                                              
 
 
 
2,4-Diethyl-5-{[(4-methoxybenzyl)oxy]carbonyl}-6-phenylpyridine-3-carbothioic 
S-acid (6) was dissolved in dry dichloromethane in a three-necked-flask equipped 
with reflux condenser and thermometer under argon atmosphere and cooled to 
0°C in an ice bath. Then triethyl silane and formic acid were added via syringe. No 
considerable rise in temperature was observed. The ice bath was removed and the 
solution stirred for further two hours. The colour of the solution changed to 
yellow. Afterwards, the solvent was evaporated under reduced pressure and the 
crude product was purified by reversed-phase column chromatography eluting 
with an acetonitrile/water mixture 95+5. Only about 19% of SUPPY:0 (7) was 
obtained from this attempt.                                                                                                     
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2.4 Preparation of 2-fluoroethyl 4,6-diethyl-5-{[(2-fluoro 
ethyl)thio]carbonyl}-2-phenylnicotinate (10)           
 
The preparation of (9) starting from SUPPY:0 (7) can be achieved by 3 different 
routes:  
 
1. 2-fluoroethylation of the carboxylate function prior to the 2-fluoro 
ethylation of the thiocarboxylate function                                                   
2. 2-fluoroethylation of the thiocarboxylate function prior to the 2-fluoro 
ethylation of the carboxylate function                                                                 
3. In a microwave-assisted single-step reaction                                                         
 
 
2.4.1 Microwave-assisted preparation of 2,4-diethyl-5-[(2-
fluoroethoxy)carbonyl]-6-phenylpyridine-3-carbothioic S-
acid71 (9) 
 
 
 
4,6-Diethyl-2-phenyl-5-thiocarboxynicotinic acid (7), 2-fluoroethyl trifluoro 
methanesulfonate and caesium carbonate were suspended in acetonitrile in a 
quartz glass vessel and put to the reaction chamber. The microwave parameters 
were set to 300 W, 150°C and 10 minutes reaction time. Caesium carbonate serves 
for two purposes, as a dipole supposed to superheat the solvent and acting as base 
to deprotonize the carboxylic acid.                                                                                         
 
Caused by a defective temperature sensor the reaction was abrupted after 2:36 
minutes. Nevertheless, about 70 % product was obtained. In prior attempts71, a 
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total reaction time of 10 minutes was sufficient to get about 90 % yield. The 
solvent was removed under reduced pressure and the crude product purified by 
reversed-phase column chromatography eluting with acetonitrile.                               
 
 
2.4.2 Preparation of 2-fluoroethyl 4,6-diethyl-5-{[(2-fluoroethyl) 
thio]carbonyl}-2-phenylnicotinate (10)                 
 
 
The second step comprises the fluoroethylation of the product obtained in the 
previous step.  
 
 
 
2,4-Diethyl-5-[(2-fluoroethoxy)carbonyl]-6-phenylpyridine-3-carbothioic S-acid 
(9) obtained from the previous step, sodium iodide and 2-fluoroethyl 
trifluoromethanesulfonate were suspended in acetonitrile in a round-bottomed 
flask equipped with reflux condenser and heated under reflux for 15-20 minutes. 
Acetonitrile, however, proved to be an unsuitable solvent, because no reaction 
progress could be observed. Furthermore, the addition of caesium carbonate as in 
the step before did not lead to a successful reaction. 
 
Although the use of DMF as solvent is accompanied by some disadvantages, it 
should replace the inappropriate acetonitrile. 
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As a consequence, 2,4-diethyl-5-[(2-fluoroethoxy)carbonyl]-6-phenylpyridine-3-
carbothioic S-acid (9) from the step earlier, sodium iodide and 2-fluoroethyl 
trifluoromethanesulfonate were dissolved in DMF in a round-bottomed flask 
equipped with reflux condenser and heated for 15-20 minutes under reflux. No 
adding of caesium carbonate was necessary. The reaction mixture had a dark 
orange colour. Then the solvent was removed by ball tube distillation and 
additional drying on a vacuum pump. The crude product was purified several 
times by reversed-phase column chromatography eluting with an 
acetonitrile/water mixture 9+1. Highly viscous orange oil was obtained. NMR and 
high-resolution mass spectra revealed the successful preparation of the product. 
 
 
2.4.3 Microwave assisted single-step preparation of 2-fluoroethyl 
4,6-diethyl-5-{[(2-fluoroethyl)thio]carbonyl}-2-
phenylnicotinate (10) 
 
During the attempt of the microwave-assisted preparation of 4,6-diethyl-5-{[(2-
fluoroethyl)thio]carbonyl}-2-phenylnicotinic acid (8), a lucky coincidence 
occurred to give the product 2-fluoroethyl 4,6-diethyl-5-{[(2-fluoroethyl) 
thio]carbonyl}-2-phenylnicotinate (10) in one single step.                                              
 
 
 
4,6-Diethyl-2-phenyl-5-thiocarboxynicotinic acid (7), sodium iodide and 2-
fluoroethyl trifluoromethanesulfonate were dissolved in DMF in a quartz glass 
vessel. Microwave power was set to 600 W, thus doubling the usual power setting 
and the temperature limit was set to 170°C and 5 minutes reaction time. These 
parameters obviously resulted in preferring of the product (10) over (8). Most 
remarkably, neither additional amount of 2-fluoroethyl trifluoromethanesulfonate 
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nor adding of caesium carbonate was necessary to lead successfully to product 
(10).  
The reaction mixture was of light yellow colour. The solvent was removed by ball 
tube distillation and additional drying on a vacuum pump. The crude product was 
purified several times by reversed-phase column chromatography eluting with 
acetonitrile/water 9+1. Compound (10) was obtained as highly viscous oil. 
 
 
2.5 Preparation of methyl 4,6-diethyl-5-{[(2-fluoroethyl) 
thio]carbonyl}-2-phenylnicotinate (11) 
 
The preparation of desired compound (11) was achieved in two steps starting 
from SUPPY:0 (7). First the thiocarboxylate group was fluoroethylated followed 
by the methylation of the carboxylate function. Furthermore, the first step was 
performed using conventional preparation and microwave assisted preparation in 
order to compare yield rates. 
 
 
2.5.1 Preparation of 4,6-diethyl-5-{[(2-fluoroethyl)thio]carbonyl}-
2-phenylnicotinic acid (8) 
 
 
 
4,6-Diethyl-2-phenyl-5-thiocarboxynicotinic acid (7), sodium iodide and 2-
fluoroethyl trifluoromethanesulfonate were dissolved in DMF in a round-
bottomed flask equipped with reflux condenser and heated for 15-20 minutes 
under reflux. During this time, the reaction mixture turned to orange colour. The 
solvent was removed by ball tube distillation. The residue was dissolved in ethyl 
acetate and alkalized with a 2N sodium hydroxide solution. The organic layer was 
extracted with water and the aqueous layer was concentrated under reduced 
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acidified with 2N hydrochloric acid, and thoroughly extracted with ethyl acetate. 
The solvent was removed under reduced pressure and the crude product purified 
by reversed-phase column chromatography eluting with acetonitrile/water 9+1. 
Colourless crystals of (8) were obtained. Pre-purification by extraction was not 
necessary employing the conventional method; nevertheless, it is a reasonable 
method leading to a pure product. 
 
 
2.5.2 Microwave-assisted preparation of 4,6-diethyl-5-{[(2-fluoro 
ethyl)thio]carbonyl}-2-phenylnicotinic acid (8) 
 
As in the step of the microwave-assisted fluoroethylation of the carboxylic acid 
(see 2.4.1.), it was attempted to fluoroethylate the thiocarboxylate function 
selectively. Trying to avoid the tedious purification steps using the solvent DMF 
and the previous successful attempt of the preparation of (9) were the reason to 
select acetonitrile as solvent.  
 
 
 
As a consequence, 4,6-diethyl-2-phenyl-5-thiocarboxynicotinic acid (7), 2-
fluoroethyl trifluoromethanesulfonate and sodium iodide were suspended in 
acetonitrile in a quartz glass vessel. Microwave parameters were set to 600 W, 
150°C and 10 minutes reaction time. After 10 minutes almost no conversion of the 
reactant had been noticed, so it was decided to continue for further 10 minutes. 
Unfortunately, TLC monitoring did not show any successful reaction. 
 
In the second attempt, the solvent was replaced by DMF (all microwave 
parameters remained unchanged). This time the reactant had been converted 
almost completely, but only the “wrong” product (10) was obtained (see 2.4.3). 
This lucky coincidence caused me to change the microwave parameters.  
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Power setting was now adjusted to 300 W and the temperature limit was 
decreased to 100°C. These settings proved to be successful as shown below.  
After the reaction, the solvent was removed under reduced pressure. The residue 
was dissolved in ethyl acetate and alkalized with a 2N sodium hydroxide solution. 
The organic layer was extracted with water. The aqueous layer was concentrated 
under reduced pressure, acidified with 2N hydrochloric acid, and thoroughly 
extracted with ethyl acetate. The solvent was removed under reduced pressure and 
the crude product purified by reversed-phase column chromatography eluting 
with acetonitrile/water 9+1. 
 
 
 
However, scaling up of this reaction showed some unexpected consequences. 
First, the yield of product was lower. Furthermore, increasing the reaction time 
did not show any effect. Some of the reactant remained unchanged. The more 
worrying disadvantage occurred during the purification process. Some 
contamination virtually undetectable on TLC sheet, but detectable via NMR 
spectra required additional purification steps. A pre-purification was carried out 
by extracting several times. Column chromatography using different eluent 
combinations (acetonitrile/water 9+1, ethyl acetate, dichloromethane/methanol 
95+5) was performed. Yet, the contamination could not be entirely eliminated. 
Considering the time necessary for making preparations for use of the microwave 
oven and the following tedious purification process, the microwave-assisted 
approach is not favourable over the conventional route.  
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2.5.3 Preparation of methyl 4,6-diethyl-5-{[(2-fluoroethyl)thio] 
carbonyl}-2-phenylnicotinate72 (11) 
 
 
 
4,6-Diethyl-5-{[(2-fluoroethyl)thio]carbonyl}-2-phenylnicotinic acid (8), 
obtained from either the reaction at 2.5.1. or 2.5.2 was dissolved in a mixture of 
toluene/methanol 3+2 in a round-bottomed flask and stirred.                                       
(Diazomethyl)trimethylsilane solution in hexane was added under continuous 
stirring until the yellow colour persisted. The stirring was continued for 30 
minutes. The progress of the reaction was observed via TLC monitoring. 
Additional (diazomethyl)trimethylsilane solution was added and the stirring 
continued. After an overall stirring time of one hour, no further progress could be 
observed. The solvent was removed under reduced pressure and the crude product 
was purified by reversed-phase column chromatography, eluting with 
acetonitrile/water 9+1.   
 
Compound (11) was obtained as colourless crystals. 
 
The contaminated reactant (8) of the microwave-assisted approach yielded only 
about 25%, a further reason why not to recommend the microwave assisted 
preparation of (8). 
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3. EXPERIMENTS   
 
3.1 Technical Equipment 
 
Recording of spectra: 
 
Mass spectra: Shimadzu QP 1000 (EI, 70eV), direct inlet 
 
High resolution mass spectra: Finnigan MAT 8230 (EI, 70eV) and Finnigan 
MAT 900 S (ESI, 4 kV, 3 µA CH3CN/MeOH).  
1H, 13C NMR-Spectra: Bruker Avance DPX-200 spectrometer at 27 °C (200.13 
MHz for 1H, 50.32 MHz for 13C). The solvent signal is used as internal reference 
standard related to TMS, occurring at δ = 7.26 ppm (1H in CDCl3), δ = 2.49 ppm 
(1H in DMSO-d6), δ = 77.0 ppm (13C in CDCl3) and δ = 39.5 ppm (13C in DMSO-
d6). 
Infrared spectra: Perkin-Elmer FTIR spectrometer Spectrum 1000 (KBr 
pellets). 
 
Chromatographic separation: 
 
Thin layer chromatography: Merck TLC Silica Gel 60 F254 aluminium sheets, 
layer thickness 0.2 mm; Merck TLC Silica Gel 60 RP-18 F254s aluminium sheets, 
layer thickness 0.2 mm. 
Column chromatography: Merck Silica Gel 60 F254; Merck Silica Gel 60 RP-
18 F254s 
 
Other equipment: 
 
Melting point determination: Reichert-Kofler hot-stage microscope 
CHN analysis: Microanalytic Laboratory, University of Vienna 
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3.2 Preparation of 4,6-diethyl-2-phenyl-5-thiocarboxy 
nicotinic  acid (7)71 
 
3.2.1 Preparation of 3-allyl 5-(4-methoxybenzyl) 2,4-diethyl-6-
phenyl-1,4-dihydropyridine-3,5-dicarboxylate (2)71 
 
 
 
4-Methoxybenzyl-3-amino-3-phenylprop-2-enoate (1a) (2.57 g, 9.10 mmol), allyl-
3-oxo-pentanoate (1c) (1.42 g, 9.10 mmol) and propionaldehyde (1b) (0.53 g, 
9.10 mmol) are dissolved in 20 ml absolute ethanol and stirred in the autoclave at 
80°C for 24 hours. The solvent is removed after cooling down to room 
temperature and the crude product purified by column chromatography 
(ligroine/EtOAc 8+2).  
 
Yield: 3.61 g (86 %; yellow-greenish oil). 
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3.2.2 Preparation of 3-allyl 5-(4-methoxybenzyl) 2,4-diethyl-6-
phenylpyridine-3,5-dicarboxylate (3)71 
 
 
 
3-Allyl 5-(4-methoxybenzyl) 2,4-diethyl-6-phenyl-1,4-dihydropyridine-3,5-
dicarboxylate (2) (3.61 g, 7.82 mmol) and 2,3,5,6-tetrachloro-1,4-benzoquinone 
(2.13 g, 8.66 mmol) are dissolved in 250 ml THF and heated under reflux 
overnight. The reaction mixture is cooled down and the solvent removed under 
reduced pressure to give the desired pyridine derivative (3). The crude product is 
purified by column chromatography (ligroine/EtOAc 9+1).                                            
 
Yield: 1.70 g (47 %; orange-brownish oil). 
 
3.2.3 Preparation of 2,4-diethyl-5-{[(4-methoxybenzyl) 
oxy]carbonyl}-6-phenylnicotinic acid (4)71 
 
 
 
3-Allyl-5-(4-methoxybenzyl)-2,4-diethyl-6-phenylpyridine-3,5-dicarboxylate (3) 
(0.93 g, 2.02 mmol), obtained from the previous step are dissolved in 15 ml THF 
and then tetrakis(triphenylphosphine)palladium (0.28 g, 0.20 mmol, 10 mol-%) 
and morpholine (2.11 g, 2.12 ml, 24.21 mmol) are added under argon atmosphere. 
The mixture is stirred for 30 minutes at room temperature. The solvent is 
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removed under reduced pressure and the crude product is purified by column 
chromatography (CH2Cl2/CH3OH 95+5 and EtOAc/MeOH 8+2). 
 
Yield: 806 mg (95 %; yellow crystals, mp. 137-139° C). 
 
  
3.2.4 Preparation of 4-methoxybenzyl 5-(chlorocarbonyl)-4,6-
diethyl-2-phenylnicotinate (5)71 
 
 
 
2,4-Diethyl-5-{[(4-methoxybenzyl)oxy]carbonyl}-6-phenylnicotinic acid (4) (1.00 
g, 2.38 mmol) is dissolved in 10 ml dry toluene under inert gas apparatus and 
cooled down to -20°C. 3 drops of DMF and oxalyl chloride (1 ml) are added drop 
wise. After reaching room temperature, the mixture is stirred for 1 hour. The 
solvent is removed under reduced pressure at a temperature below 32°C. The 
crude product is used immediately for the next reaction step (see 3.2.5).                     
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3.2.5 Preparation of 2,4-diethyl-5-{[(4-methoxybenzyl)oxy] 
carbonyl}-6-phenylpyridine-3-carbothioic S-acid (6)71 
 
 
 
NaHS.hydrate platelets (0.36 g, 6.45 mmol) are dissolved in 10 ml of absolute 
ethanol under moderate heating. The solution is cooled down to -20° C. To this 
solution, the crude 4-methoxybenzyl 5-(chlorocarbonyl)-4,6-diethyl-2-
phenylnicotinate (5), obtained from the previous reaction, dissolved in 4 ml of dry 
THF is added slowly under stirring. After the adding has finished, the reaction 
mixture is allowed to reach room temperature. The stirring is continued for 
approximately one hour until the reaction is complete. The orange solution is 
acidified by 6N HCl solution. The aqueous layer is extracted thoroughly with 
EtOAc, washed twice with a saturated NaCl solution, and dried over Na2SO4. The 
solvent is removed under reduced pressure and the crude product purified by 
column chromatography several times (ligroine/EtOAc 7+3).                                         
 
Yield: 480 mg (46 %) colourless crystals, mp. 59-60° C. 
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3.2.6 Preparation of 4,6-diethyl-2-phenyl-5-thiocarboxynicotinic 
acid (SUPPY:0) (7)71 
 
 
 
2,4-Diethyl-5-{[(4-methoxybenzyl)oxy]carbonyl}-6-phenylpyridine-3-carbothioic 
S-acid (6) (1.00 g, 2.29 mmol) from the previous reaction step is stirred in the 
presence of 10 ml HCOOH at room temperature for several hours. The solvent is 
removed under reduced pressure and the crude product is purified by reversed-
phase column chromatography (CH3CN/H2O mixture 95+5).  
 
Yield: 300 mg (41.5 %; colourless crystals, mp. 191° C). 
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3.2.6.1 Deprotection with triethyl silane / trifluoroacetic acid 
 
 
 
2,4-Diethyl-5-{[(4-methoxybenzyl)oxy]carbonyl}-6-phenylpyridine-3-carbothioic 
S-acid (6) (0.10 g, 0.23 mmol) are dissolved in 7 ml of absolute CH2Cl2 under 
argon atmosphere and cooled to 0° C. Triethyl silane (913 µl, 5.74 mmol) and 
trifluoroacetic acid (2.2 ml, 28.56 mmol) are added slowly. After reaching room 
temperature, the solution is stirred for further two hours. In the following, the 
solvent is removed under reduced pressure. The crude product is purified by 
reversed-phase column chromatography (CH3CN/H2O 95+5).  
 
Yield: 30 mg (41.4 %; colourless crystals, mp. 191° C). 
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3.3 Preparation of 2-fluoroethyl 4,6-diethyl-5-{[(2-fluoro 
ethyl)thio]carbonyl}-2-phenylnicotinate (10) 
 
 
3.3.1 Microwave-assisted preparation of 2,4-diethyl-5-[(2-
fluoroethoxy)carbonyl]-6-phenylpyridine-3-carbothioic S-
acid (9)71 
 
 
 
4,6-Diethyl-2-phenyl-5-thiocarboxynicotinic acid (7) (0.10 g, 0.32 mmol), 2-
fluoroethyl trifluoromethanesulfonate (0.14 g, 0.66 mmol) and Cs2CO3 (0.22 g, 
0.66 mmol) are suspended in 10 ml of CH3CN. The mixture is heated in the 
microwave oven at 300 W and 150° C for 10 minutes. The solvent is removed 
under reduced pressure and the crude product purified by reversed-phase column 
chromatography (CH3CN). 
 
Yield: 80 mg (69.2 %; colourless crystals, mp. 45-47° C).  
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3.3.2 Preparation of 2-fluoroethyl 4,6-diethyl-5-{[(2-fluoroethyl) 
thio]carbonyl}-2-phenylnicotinate (10) 
 
 
 
 
2,4-Diethyl-5-[(2-fluoroethoxy)carbonyl]-6-phenylpyridine-3-carbothioic S-acid 
(9) (0.08 g, 0.22 mmol) from the previous reaction step, NaI (0.33 g, 2.2 mmol) 
and 2-fluoroethyl trifluoromethanesulfonate (0.12 g, 0.61 mmol) are dissolved in 
10 ml of DMF and heated under reflux for 15-20 minutes. The solvent is removed 
by ball tube distillation and additional drying on a vacuum pump. The crude 
product is purified by reversed-phase column chromatography (CH3CN/H2O 9+1). 
 
Yield: 51 mg (56.9 %; orange oil). 
 
 
3.3.3 Microwave assisted single-step preparation of 2-fluoroethyl 
4,6-diethyl-5-{[(2-fluoroethyl)thio]carbonyl}-2-
phenylnicotinate (10) 
 
 
 
4,6-Diethyl-2-phenyl-5-thiocarboxynicotinic acid (7) (0.073 g, 0.23 mmol), NaI 
(0.348 g, 2.3 mmol) and 2-fluoroethyl trifluoromethanesulfonate (0.11 g, 0.56 
mmol) are dissolved in 10 ml of DMF. The mixture is heated in the microwave 
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oven at 600 W and 170° C for 5 minutes. The solvent is removed under reduced 
pressure and the crude product purified by reversed-phase column 
chromatography (CH3CN/H2O 9+1). 
 
Yield: 67 mg (71.5 %; orange oil). 
 
 
Spectroscopic Data:  
 
1H NMR (Chart 1.1.) (200 MHz, CDCl3) δ (ppm): 7.60 (m, 2H), 7.43 (m, 3H), 
4.77 (t, 1H, J = 5.99 Hz), 4.54 (t, 1H, J = 5.94 Hz), 4.42 (m, 1H), 4.34 (q, 1H, J = 
2.48 Hz), 4.18 (d, 2H, J = 5.18 Hz), 3.52 (t, 1H, J = 5.99 Hz), 3.41 (t, 1H, J = 5.94 
Hz), 2.87 (q, 2H, J= 7.49 Hz), 2.73 (q, 2H, J = 7.53 Hz), 1.34 (t, 3H, J = 7.51 Hz), 
1.24 (t, 3H, J = 7.57 Hz). 
 
13C-NMR (Chart 1.2) (50 MHz, CDCl3) δ (ppm): 194.3, 168.1, 159.6, 157.5, 
148.2, 139.6, 132.6, 129.0, 128.4, 128.3, 126.0, 83.0, 82.2, 79.6, 78.8, 64.3, 63.9, 
30.2, 29.8, 29.2, 24.2, 15.7, 14.0. 
 
IR (Chart 1.3) (KBr): v (cm-1) 3447, 2977, 2879, 1734, 1675, 1558, 1496  
 
MS (Chart 1.4): m/z (%): 407 (M+, 0.59), 329 (21), 328 (100), 282 (6), 254 (6), 
236 (5), 47 (6). 
 
HRMS (Chart 1.5): m/z calculated for C21H23O3F2NSH: 408.1445. Found: 
408.1450.    
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3.4 Preparation of methyl 4,6-diethyl-5-{[(2-fluoroethyl) 
thio]carbonyl}-2-phenylnicotinate (11) 
 
 
3.4.1 Preparation of 4,6-diethyl-5-{[(2-fluoroethyl)thio]carbonyl}-
2-phenylnicotinic acid (8) 
 
 
 
4,6-Diethyl-2-phenyl-5-thiocarboxynicotinic acid (7) (0.10 g, 0.32 mmol), NaI 
(0.476 g, 3.2 mmol) and 2-fluoroethyl trifluoromethanesulfonate (0.14 g, 0.71 
mmol) are dissolved in 10 ml of DMF and heated under reflux for 15-20 minutes. 
The solvent is removed by ball tube distillation. The residue is dissolved in EtOAc 
and alkalized with a 2N NaOH solution. The organic layer is extracted with water. 
The aqueous layer is concentrated under reduced pressure, acidified with 2N HCl 
solution, and thoroughly extracted with EtOAc. The solvent is removed under 
reduced pressure and the crude product purified by reversed-phase column 
chromatography (CH3CN/H2O 9+1).  
 
Yield: 79 mg (68.3 %; colourless crystals, mp. 195-196° C).  
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3.4.2 Microwave-assisted preparation of 4,6-diethyl-5-{[(2-
fluoroethyl)thio]carbonyl}-2-phenylnicotinic acid (8) 
 
 
 
4,6-Diethyl-2-phenyl-5-thiocarboxynicotinic acid (7) (0.05 g, 0.16 mmol), 2-
fluoroethyl trifluoromethanesulfonate (0.07 g, 0.36 mmol), and NaI (0.539 g, 3.6 
mmol) are dissolved in 10 ml of DMF. The reaction mixture is heated in the 
microwave oven at 300 W and 100° C for 10 minutes. The solvent is removed by 
ball tube distillation. The residue is dissolved in EtOAc and alkalized with a 2N 
NaOH solution. The organic layer is extracted with water. The aqueous layer is 
concentrated under reduced pressure, acidified with 2N HCl solution, and 
thoroughly extracted with EtOAc. The solvent is removed under reduced pressure 
and the crude product purified by reversed-phase column chromatography 
(CH3CN/H2O 9+1).  
 
Yield: 30 mg (51.9 %; colourless crystals, mp. 195-196 °C).  
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3.4.3 Preparation of methyl 4,6-diethyl-5-{[(2-fluoroethyl)thio] 
carbonyl}-2-phenylnicotinate (11)                    
 
 
 
 
4,6-Diethyl-5-{[(2-fluoroethyl)thio]carbonyl}-2-phenylnicotinic acid (8) (0.079 g, 
0.22 mmol) are dissolved in 10 ml of a mixture of toluene/methanol 3+2. 
(Diazomethyl)trimethylsilane solution in hexane 2.0M (0.16 ml, 0.33 mmol) is 
added under continuous stirring until the yellow colour persists. The stirring is 
continued for 30 minutes. If the reaction is incomplete, additional 
(diazomethyl)trimethylsilane solution in hexane 2.0M is added (0.16 ml, 0.33 
mmol) and stirring continued for further 30 minutes. After an overall stirring of 
one hour the reaction is stopped. The solvent is removed under reduced pressure 
and the crude product purified by reversed-phase column chromatography 
(acetonitrile/water 9+1).    
 
Yield: 73 mg (88.4 %; colourless crystals, mp. 55-57° C). 
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Spectroscopic Data:  
 
1H NMR (Chart 2.1) (200 MHz, CDCl3) δ (ppm): 7.59 (q, 2H, J = 2.86 Hz), 7.44 
(m, 3H), 4.77 (t, 1H, J = 5.93 Hz), 4.54 (t, 1H, J = 5.99 Hz), 3.63 (s, 3 H), 3.51 (t, 
1H, J = 5.99 Hz), 3.40 (t, 1H, J = 6.00 Hz), 2.86 (q, 2H, J = 7.50 Hz), 2.71 (q, 2H, 
J = 7.58 Hz), 1.34 (t, 3H, J = 7.45 Hz), 1.22 (t, 3H, J = 7.57 Hz). 
 
13C-NMR (Chart 2.2) (50 MHz, CDCl3) δ (ppm): 194.5, 168.9, 159.4, 157.1, 
148.1, 139.6, 132.6, 128.4, 128.2, 126.3, 83.0, 79.6, 52.3, 30.2, 29.8, 29.2, 24.2, 
15.7, 13.9. 
 
IR (Chart 2.3) (KBr): v (cm-1) 3427, 2975, 2884, 1725, 1653, 1558, 1495. 
 
MS (Chart 2.4): m/z (%): 375 (M+, 0.90), 297 (18), 296 (100), 264 (5), 236 (8).  
 
HRMS (Chart 2.5): m/z calculated for C20H22O3FNSH: 376.1383. Found: 
376.1392.    
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5.2 Abstract 
 
 
In the past 3 decades, the development of positron emission tomography (PET) 
has made great progress. It has become a powerful imaging technique for medical 
diagnostic as well as answering many questions of physiological, biochemical or 
pharmacokinetic interest. Apart from the technical evolution of the PET scanners, 
the development of new tracer molecules was a prerequisite necessary for the 
success of this technique.  
Among others, the adenosine A3 receptor and its properties has become of major 
interest since many of its biological functions remained unclear. Subsequently, the 
preparation of numerous possible PET tracer molecules began.   
Eventually, a series of suitable PET antagonists, comprising a sulfanyl-phenyl-
pyridine structure, were developed.  
 
In the submitted thesis the preparation of two novel adenosine-A3-receptor 
antagonists are described.  
They are 2-fluoroethyl 4,6-diethyl-5-{[(2-fluoroethyl)thio]carbonyl}-2-
phenylnicotinate (10) and methyl 4,6-diethyl-5-{[(2-fluoroethyl)thio] carbonyl}-
2-phenylnicotinate (11).                                                                                    
Another task was a new synthesis pathway to obtain 4,6-diethyl-5-{[(2-
fluoroethyl)thio]carbonyl}-2-phenylnicotinic acid (8).  
 
 
 
These three molecules should serve as HPLC reference compounds and need 
further investigation regarding their receptor binding qualities. 
 
 
  
5.3 Zusammenfassung 
 
 
In den vergangenen 3 Jahrzehnten hat die Entwicklung der Positronen-
Emissions-Tomographie große Fortschritte erzielt. Sie wurde ein wichtiges 
bildgebendes Verfahren, sowohl für die medizinische Diagnostik als auch die 
Forschung. Sie ermöglicht die Beantwortung vieler Fragestellungen in der 
Physiologie, Biochemie und der Pharmakokinetik.  
Abgesehen von der technischen Evolution der PET-Scanner selbst, war die 
Entwicklung neuer Tracer eine Voraussetzung für den Erfolg der Methode. 
Neben anderen wurde der Adenosin-A3-Rezeptor und dessen Eigenschaften zum 
Gegenstand der Forschung, da viele seiner biologischen Funktionen bis dato 
ungeklärt waren. Dies führte zur Entwicklung einer Reihe potenzieller PET-
Tracer. 
Schließlich wurde eine Serie geeigneter PET-Antagonisten, bestehend aus einem 
Sulfanyl-phenyl-pyridin-Grundgerüst, entwickelt. 
 
In der vorgelegten Arbeit wird die Synthese zweier Adenosin-A3-Rezeptor-
Antagonisten beschrieben. 
Die zwei Moleküle sind 2-Fluorethyl 4,6-diethyl-5-{[(2-fluorethyl)thio] carbonyl}-
2-phenylnicotinat (10) und Methyl 4,6-diethyl-5-{[(2-fluorethyl)thio]carbonyl}-
2-phenylnicotinat (11).                                                                                                             
Die zweite Aufgabe war ein neuer Syntheseweg für 4,6-diethyl-5-{[(2-
fluorethyl)thio]carbonyl}-2-phenylnicotinsäure (8).  
 
 
 
Diese 3 Moleküle sollen als HPLC Referenzsubstanzen dienen und werden in 
Zukunft möglicherweise auf ihre Rezeptorbindungseigenschaften getestet.  
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